Key result
DOAC use linked to ~74% lower upper GI bleeding risk vs. warfarin after H. pylori eradication.
Why the study?
To investigate the risks of hospitalization for upper gastrointestinal bleeding in H. pylori-eradicated patients newly started on warfarin or direct oral anticoagulants.
Do DOACs reduce the risk of hospitalization for upper gastrointestinal bleeding compared to warfarin in H. pylori-eradicated patients?
Cohort
Do DOACs reduce the risk of hospitalization for upper gastrointestinal bleeding compared to warfarin in H. pylori-eradicated patients?
In H. pylori-eradicated patients requiring anticoagulation, DOACs are associated with a significantly lower risk of upper gastrointestinal bleeding compared to warfarin.
Answers are grounded in this paper and cite their sources.
DOACs were associated with lower UGIB risk than warfarin in H. pylori-eradicated patients; hypothesis-generating and should not yet change practice.
BACKGROUND: To investigate risks of hospitalization for upper gastrointestinal bleeding (UGIB) in H. pylori-eradicated patients newly started on warfarin or direct oral anti-coagulants (DOACs). METHODS: We identified all patients who had previously received H. pylori eradication therapy or were found to have no H. pylori on endoscopy and were then newly started on warfarin or DOACs from a population-based electronic healthcare database. Primary analysis was the risk of UGIB between warfarin and DOACs users in H. pylori-eradicated patients. Secondary analysis included the UGIB risk between H. pylori-eradicated and H. pylori-negative patients who were newly started on warfarin or DOACs. The hazard ratio (HR) of UGIB was approximated by pooled logistic regression model incorporating the inverse propensity of treatment weightings with time-varying covariables. RESULTS: Among H. pylori-eradicated patients, DOACs had a significantly lower risk of UGIB (HR: 0.26, 95% CI 0.09-0.71) compared with warfarin. In particular, lower UGIB risks with DOACs were observed among older (≥65 years) patients, female, those without a history of UGIB or peptic ulcer, or ischemic heart disease, and non-users of acid-suppressive agents or aspirin. Secondary analysis showed no significant difference in UGIB risk between H. pylori-eradicated and H. pylori-negative patients newly started on warfarin (HR: 0.63,95% CI 0.33-1.19) or DOACs (HR: 1.37, 95% CI 0.45-4.22). CONCLUSIONS: In H. pylori-eradicated patients, new users of DOACs had a significantly lower risk of UGIB than new warfarin users. Furthermore, the risk of UGIB in new warfarin or DOACs users was comparable between H. pylori-eradicated and H. pylori-negative patients.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2023) conducted a cohort in Helicobacter pylori eradication requiring anticoagulation. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Hospitalization for upper gastrointestinal bleeding (UGIB) (HR 0.26, 95% CI 0.09-0.71). Among H. pylori-eradicated patients, new users of direct oral anticoagulants had a lower risk of hospitalization for upper gastrointestinal bleeding compared with new warfarin users.
Synapse has enriched 10 related papers. Consider them for comparative context: